Amgen Inc. $AMGN Shares Sold by Avity Investment Management Inc.

Avity Investment Management Inc. trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,921 shares of the medical research company’s stock after selling 2,452 shares during the period. Amgen accounts for 1.6% of Avity Investment Management Inc.’s holdings, making the stock its 26th biggest position. Avity Investment Management Inc.’s holdings in Amgen were worth $23,213,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Board of the Pension Protection Fund purchased a new position in Amgen during the fourth quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new position in Amgen during the second quarter worth about $32,000. Olistico Wealth LLC purchased a new position in Amgen during the fourth quarter worth about $33,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $34,000. Finally, Saranac Partners Ltd purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $348.77 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The firm’s fifty day simple moving average is $362.59 and its 200-day simple moving average is $329.87. The firm has a market capitalization of $188.01 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 3.50 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. TD Cowen reissued a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Morgan Stanley increased their target price on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Finally, Argus upped their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.